This is a major milestone for Truion.
The grant of our European patent reflects years of scientific work, development, and validation. It is also an important recognition of the innovation behind our technology. At the same time, it strengthens Truion’s development roadmap and market position in male infertility diagnostics.
Male infertility is still too often unexplained. With CatSper testing, we aim to help close a critical diagnostic gap in male infertility diagnostics and support more evidence-based decisions in fertility treatment.
A big thank you to everyone who contributed to this achievement.
